{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:23:42Z","timestamp":1784114622425,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jchromb.2020.122508","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T23:20:30Z","timestamp":1608333630000},"page":"122508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo"],"prefix":"10.1016","volume":"1163","author":[{"given":"Seong-Wook","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Gyun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongho","family":"Geum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwayoung","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2020.122508_b0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1756-8722-6-88","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jchromb.2020.122508_b0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MPH.0000000000000329","article-title":"PI3King the lock: targeting the PI3K\/Akt\/mTOR pathway as a novel therapeutic strategy in neuroblastoma","volume":"37","author":"King","year":"2015","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.jchromb.2020.122508_b0015","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jchromb.2020.122508_b0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/cas.13923","article-title":"Phase I study of alpelisib (BYL719), an alpha-specific PI3K inhibitor Japanese patients with advanced solid tumors","volume":"110","author":"Ando","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jchromb.2020.122508_b0025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","article-title":"Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer","volume":"17","author":"Katso","year":"2001","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.jchromb.2020.122508_b0030","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jchromb.2020.122508_b0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"N. Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jchromb.2020.122508_b0040","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature11154","article-title":"Sequence analysis of mutations and translocations across breast cancer subtypes","volume":"486","author":"Banerji","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jchromb.2020.122508_b0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","author":"N. Cancer Genome Atlas Research","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jchromb.2020.122508_b0050","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"N. Cancer Genome Atlas Research","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jchromb.2020.122508_b0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jchromb.2020.122508_b0060","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1158\/1078-0432.CCR-04-2142","article-title":"Frequent mutation of the PIK3CA gene in ovarian and breast cancers","volume":"11","author":"Levine","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jchromb.2020.122508_b0065","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-kinase alpha-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study","volume":"36","author":"Juric","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jchromb.2020.122508_b0070","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","article-title":"Alpelisib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jchromb.2020.122508_b0075","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","article-title":"Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials","volume":"13","author":"Fritsch","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jchromb.2020.122508_b0080","doi-asserted-by":"crossref","first-page":"196ra199","DOI":"10.1126\/scitranslmed.3005747","article-title":"mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer","volume":"5","author":"Elkabets","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jchromb.2020.122508_b0085","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00280-015-2842-4","article-title":"Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers","volume":"76","author":"James","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.122508_b0090","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bcp.12378","article-title":"Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies","volume":"78","author":"De Buck","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.122508_b0095","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1210\/endo.141.9.7636","article-title":"A link between insulin resistance and hyperinsulinemia: inhibitors of phosphatidylinositol 3-kinase augment glucose-induced insulin secretion from islets of lean, but not obese, rats","volume":"141","author":"Zawalich","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.jchromb.2020.122508_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jchromb.2019.05.023","article-title":"A novel high-performance liquid chromatographic method combined with fluorescence detection for determination of ertugliflozin in rat plasma: Assessment of pharmacokinetic drug interaction potential of ertugliflozin with mefenamic acid and ketoconazole","volume":"1122\u20131123","author":"Han","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2020.122508_b0105","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1039\/D0AY00471E","article-title":"A sensitive HPLC-FL method to simultaneously determine febuxostat and diclofenac in rat plasma: assessment of metabolic drug interactions in vitro and in vivo","volume":"12","author":"Han","year":"2020","journal-title":"Anal. Methods"},{"key":"10.1016\/j.jchromb.2020.122508_b0110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/pharmaceutics11080382","article-title":"Pharmacokinetic evaluation of metabolic drug interactions between repaglinide and celecoxib by a bioanalytical HPLC method for their simultaneous determination with fluorescence detection","volume":"11","author":"Han","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jchromb.2020.122508_b0115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40005-018-00416-w","article-title":"Comparison of UPLC-MS\/MS and HPLC-UV methods for the determination of zaltoprofen in human plasma","volume":"49","author":"Jang","year":"2019","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jchromb.2020.122508_b0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12272-015-0697-1","article-title":"Development and validation of a highly sensitive LC-MS\/MS method for the determination of acacetin in human plasma and its application to a protein binding study","volume":"39","author":"Kim","year":"2016","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jchromb.2020.122508_b0125","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/00498254.2012.700139","article-title":"Saturable sinusoidal uptake is rate-determining process in hepatic elimination of docetaxel in rats","volume":"42","author":"Yoon","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jchromb.2020.122508_b0130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2016.05.002","article-title":"Poloxamer-based solid dispersions for oral delivery of docetaxel: differential effects of F68 and P85 on oral docetaxel bioavailability","volume":"507","author":"Song","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jchromb.2020.122508_b0135","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40005-017-0350-8","article-title":"In-vitro and in-vivo pharmacokinetics of IS01957, p-coumaric acid derivative using a validated LC\u2013ESI\u2013MS\/MS method in mice plasma","volume":"48","author":"Sharma","year":"2018","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jchromb.2020.122508_b0140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40005-017-0352-6","article-title":"A pharmacokinetic comparison of homodimer ARB-92 and heterodimer ARB-89: Novel, potent antimalarial candidates derived from 7\u03b2-hydroxyartemisinin","volume":"48","author":"Avery","year":"2018","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jchromb.2020.122508_b0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/j.1552-4604.1993.tb03910.x","article-title":"Bioavailability studies of drugs with nonlinear pharmacokinetics: II. absolute bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double-stable isotope technique","volume":"33","author":"Browne","year":"1993","journal-title":"J. Clin. Pharmacol."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023220313842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023220313842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:02:57Z","timestamp":1761606177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023220313842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"alternative-id":["S1570023220313842"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122508","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122508","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122508"}}